Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib and Pembrolizumab in Recurrent Glioblastoma
NCT04118036Phase 2Withdrawn
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Dec 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of abemaciclib in glioblastoma (GBM) (2 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Tumor Infiltrating Lymphocytes density in tumor tissue, Progression Free Survival at 6 months and 5 more. Planned start Dec 2021; status: withdrawn.
02
Drugs
abemaciclib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04118036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04118036.